腺病毒载体介导PDX-1在骨髓间充质干细胞中的表达

为研究PDX-1基因在骨髓间充质干细胞中的表达情况及生物学功能的发挥,构建了含PDX-1基因的重组腺病毒载体.酶切PDX-1基因并连入穿梭质粒pAdTrack-CMV.用电穿孔法使穿梭质粒pAdTrack-CMV-PDX-1与病毒骨架质粒pAdEasy-1在大肠杆菌BJ5183中同源重组.利用脂质体介导重组腺病毒载体转染293细胞,包装出完整的腺病毒.分离、培养、扩增骨髓间充质干细胞.用重组腺病毒感染间充质干细胞.用荧光显微镜、RT-PCR、免疫荧光染色等方法检测PDX-1、胰岛素基因及蛋白质的表达,用放射免疫分析法检测转基因细胞分泌胰岛素情况.结果表明:通过测序、PCR、酶切等鉴定PDX-1基因已正确插入穿梭质粒中,并与病毒骨架质粒重组.重组腺病毒滴度为6.3×107PFU/ml.通过荧光显微镜观察证实重组腺病毒可高效感染骨髓间充质干细胞,经RT-PCR、免疫荧光染色证实转染pAd-PDX-1后培养7天的细胞中有PDX-1及胰岛素基因的表达.这些转基因的细胞向胞外分泌的胰岛素量为(15.21±3.50)mIU/L.     

人骨髓间充质干细胞过表达白细胞介素-34对THP-1细胞的调节作用

构建人IL-34真核表达载体并将其转染到人骨髓间充质干细胞,观察高表达IL-34的骨髓间充质干细胞对THP-1细胞的影响。PCR扩增IL-34 DNA,并将其克隆到真核表达载体pIRES2-EGFP;将构建成功的重组体转染到骨髓间充质干细胞,Western blotting和ELISA分析IL-34在细胞中的表达;用高表达IL-34的骨髓间充质干细胞培养上清液来培养THP-1细胞,Real-time PCR分析THP-1细胞中IL-10和TNFα的表达变化。经双酶切和测序鉴定,成功构建了pIRES2-EGFP-IL-34重组体;转染至骨髓间充质干细胞的IL-34可以促进THP-1细胞表达IL-10和TNFα。结果表明,骨髓间充质干细胞表达分泌的IL-34对THP-1有调节作用。     

慢病毒重组同源盒基因HOXA4表达载体的构建及其感染人脐带间充质干细胞的实验性研究

目的 构建携带同源基因HOXA4的慢病毒表达载体,并测定其对人脐带间充质干细胞的感染效率.方法 使用酶切及PCR技术从含有HOXA4基因的质粒克隆模版HOXA4-MSCV逆转录载体中获取目的 基因HOXA4,并将HOXA4基因重组到慢病毒载体表达质粒上Lenti-GFP-CTB,通过酶切、测序验证HOXA4基因后,将Lenti-GFP-HOXA4质粒、和辅助包装质粒pRsv-REV、pMDlg-pRRE、PMD2G共同转染人胚胎肾上皮细胞系293T细胞,获得携带HOXA4基因的重组慢病毒Lentiviral-HOXA4;然后感染人脐带间充质干细胞,通过荧光显微镜及流式细胞术检测其感染效率.结果 成功构建携带HOXA4基因的慢病毒表达载体Lentiviral-HOXA4,并获得高纯度的慢病毒浓缩液.经检测病毒滴度达2.11×108 TU/ml.成功转染HOXA4基因的脐带间充质干细胞表达绿色荧光蛋白,当病毒感染复数（MOI）值为60时转染效率最高,达（95.4±4.3）%.结论 成功构建携带人HOXA4基因的慢病毒,并可以在体外有效转染人脐带间充质干细胞.     

腺病毒载体介导PDX-1在骨髓间充质干细胞中的表达

为研究PDX-1基因在骨髓间充质干细胞中的表达情况及生物学功能的发挥,构建了含PDX-1基因的重组腺病毒载体. 酶切PDX-1基因并连入穿梭质粒pAdTrack-CMV.用电穿孔法使穿梭质粒pAdTrack-CMV-PDX-1与病毒骨架质粒pAdEasy-1在大肠杆菌BJ5183中同源重组.利用脂质体介导重组腺病毒载体转染293细胞,包装出完整的腺病毒.分离、培养、扩增骨髓间充质干细胞.用重组腺病毒感染间充质干细胞.用荧光显微镜、RT-PCR、免疫荧光染色等方法检测PDX-1、胰岛素基因及蛋白质的表达,用放射免疫分析法检测转基因细胞分泌胰岛素情况.结果表明:通过测序、PCR、酶切等鉴定PDX-1基因已正确插入穿梭质粒中,并与病毒骨架质粒重组.重组腺病毒滴度为6.3×10⁷ PFU/ml.通过荧光显微镜观察证实重组腺病毒可高效感染骨髓间充质干细胞,经RT-PCR、免疫荧光染色证实转染pAd-PDX-1后培养7天的细胞中有PDX-1及胰岛素基因的表达.这些转基因的细胞向胞外分泌的胰岛素量为(15.21±3.50) mIU/L.     

Microdystrophin基因重组腺病毒的构建及转染mdx骨髓间充质干细胞的表达

构建含有人microdystrophin基因的重组腺病毒,来感染dystrophin基因敲除小鼠mdx的骨髓间充质干细胞(MSC)进行基因修饰,为同种异体基因修饰的干细胞移植治疗DMD疾病奠定基础。用NotⅠ酶切含microdystrophin基因的pBSK-MICRO质粒,获得microdystrophin基因。片段回收后定向插入腺病毒穿梭质粒pShuttle-CMV,获得重组质粒pShuttle-CMV-MICRO。PmeⅠ线性化重组质粒pShuttle-CMV-MICRO,去磷酸化后回收后与腺病毒骨架质粒pAdeasy-1共电转化BJ5183感受态细胞。同源重组后用选择性培养基筛选阳性克隆,提取质粒,用脂质体介导转染293细胞,通过观察293细胞病变及PCR扩增目的基因等方法鉴定重组的腺病毒。然后将病毒上清转染DMD模型鼠mdx小鼠的骨髓间充质干细胞,通过RT-PCR以及间接免疫荧光检测microdystrophin的转录及蛋白表达。成功构建了含有microdystrophin基因的重组腺病毒,病毒滴度为5·58×1012vp/mL。间接免疫荧光检测可见microdystrophin蛋白在mdx小鼠MSCs中高效表达。该重组腺病毒载体的构建及成功转染到mdxMSCs内表达为下一步用microdystrophin基因修饰的mdxMSCs进行同种异体移植治疗DMD疾病奠定了基础。     

真核表达载体pIRES2-EGFP-Nurr1的构建及鉴定

目的:构建带有增强型绿色荧光蛋白报告基因EGFP及目的基因Nurr1的真核表达载体pIRES2-EGFP-Nurr1,并检测其在293T细胞中的表达。方法:采用反转录-聚合酶链式反应(RT-PCR)方法从大鼠黑质中获取Nurrl基因,连接T载体测序正确后与真核空载体pIRES2-EGFP一起,经Nhe1和Xho1双酶切,T4 DNA连接酶连接,构建pIRES2-EGFP-Nurr1;真核表达载体pIRES2-EGFP-Nurr1测序正确后采用脂质体法将其转染293T细胞,倒置荧光显微镜下观察转染效率,PCR检测Nurr1基因mRNA水平的表达情况,免疫印迹试验(Western Blot)检测Nurr1蛋白的表达水平。结果:酶切及测序鉴定证实成功构建了重组真核表达载体pIRES2-EGFP-Nurr1;293T细胞转染pIRES2-EGFP-Nurr1后可以高度表达绿色荧光,有效转录Nurr1基因并正确的高表达Nurr1蛋白。结论:成功构建Nurr1真核表达载体且在293T细胞中高水平表达,为进一步转染大鼠骨髓间充质干细胞(BMSCs),基因治疗帕金森病奠定基础。     

大鼠NeuroD2基因的克隆、真核表达载体的构建及其在小鼠MSCs细胞中的表达

克隆大鼠NeuroD2基因,旨在构建p IRES2-Ac GFP1-ND2真核表达载体并检测其在小鼠MSCs中的表达。采用RTPCR技术克隆大鼠NeuroD2基因,分析该蛋白质结构、功能域、细胞定位及与其他物种同源性;构建pIRES2-AcGFP1-ND2表达载体并转染小鼠骨髓间充质干细胞(MSCs);采用Real-time PCR、免疫荧光及Western blot技术检测重组质粒在小鼠MSCs中的表达。结果表明,大鼠NeuroD2基因CDS区全长1 149 bp,共编码382个氨基酸,属于b HLH家族,二级结构以α-螺旋和无规卷曲为主,空间结构呈现近似"螺旋-环-螺旋(HLH)"结构,主要分布在细胞核,氨基酸序列与家鼠(99%)、罗猴(98%)、人(97.7%)同源性较高;Real-time PCR结果表明转染组NeuroD2基因表达量显著高于对照组(P0.05);免疫荧光及Western blot结果显示转染组NeuroD2蛋白表达量显著高于对照组(P0.05)。成功克隆大鼠NeuroD2基因并构建了pIRES2-AcGFP1-ND2真核表达载体。     

体外HCN2转染脂肪干细胞构建起搏细胞的实验研究

目的:体外HCN2基因转染人脂肪干细胞(Adipose-derived stem cells,ADSCs)构建起搏细胞.方法:取人脂肪组织分离得到脂肪干细胞并进行体外培养,Ad.HCN2转染后检测HCN2表达情况,检测转染后ADSCs自主产生起搏电流(pacemaker current,If)的能力.结果:RT-PCR结果显示实验组HCN2基因表达.Western-blot可检测到实验组HCN2蛋白表达.流式细胞仪检测可见实验组HCN2阳性比例明显升高.免疫荧光检测可见转染的ADSCs发出红色荧光.膜片钳可记录到起搏电流,其激活电位约为-60 mV,完全激活电位140mV,呈电压依赖性.结论:ADSCs被Ad.HCN2转染后可表达目的基因HCN2,并自主产生起搏电流.     

骨髓间充质干细胞分化为心肌细胞过程中Notch表达的研究

目的研究骨髓间充质干细胞分化为心肌细胞过程中Notch表达的研究。方法用密度梯度离心法分离培养犬骨髓间充质干细胞,按照酶法及差速贴壁法分离培养心肌细胞。观察干细胞增殖及传代情况。单独培养的干细胞为对照组,实验组将骨髓间充质干细胞与心肌细胞共培养,用RT-PCR、免疫细胞化学、MTT等方法检测干细胞分化为心肌细胞的情况,及干细胞在增殖与分化为心肌细胞过程中Notch信号系统的表达情况。结果骨髓间充质干细胞呈梭形、旋涡样生长,增殖及传代能力强,并可诱导分化为心肌样细胞,免疫荧光示心肌细胞标志物的表达。RT-PCR及免疫细胞化学显示实验组有Notch信号通路受体及配体的表达,而对照组表达微弱。结论骨髓间充质干细胞在增殖及分化过程中存在Notch信号通路,在干细胞分化为心肌细胞过程中Notch信号系统的表达上调。     

Microdystrophin基因重组腺病毒的构建及转染mdx骨髓间充质干细胞的表达

构建含有人microdystrophin基因的重组腺病毒,来感染dystrophin基因敲除小鼠mdx的骨髓间充质干细胞(ＭＳＣ)进行基因修饰,为同种异体基因修饰的干细胞移植治疗ＤＭＤ疾病奠定基础。用NotⅠ酶切含microdystrophin基因的pBSK-MICRO质粒,获得microdystrophin基因。片段回收后定向插入腺病毒穿梭质粒pShuttle-CMV,获得重组质粒pShuttle-CMV-MICRO。PmeⅠ线性化重组质粒pShuttle-CMV-MICRO,去磷酸化后回收后与腺病毒骨架质粒pAdeasy-1共电转化BJ5183感受态细胞。同源重组后用选择性培养基筛选阳性克隆,提取质粒,用脂质体介导转染293细胞,通过观察293细胞病变及PCR扩增目的基因等方法鉴定重组的腺病毒。然后将病毒上清转染DMD模型鼠mdx小鼠的骨髓间充质干细胞,通过RT-PCR以及间接免疫荧光检测microdystrophin的转录及蛋白表达。成功构建了含有microdystrophin基因的重组腺病毒,病毒滴度为5.58×10¹²vp/mL。间接免疫荧光检测可见microdystrophin蛋白在mdx小鼠MSCs中高效表达。该重组腺病毒载体的构建及成功转染到mdx MSCs内表达为下一步用microdystrophin基因修饰的mdx MSCs进行同种异体移植治疗ＤＭＤ疾病奠定了基础。     

小鼠DLL1真核表达载体的构建及其在肿瘤细胞中的表达

目的：构建带绿色荧光蛋白的小鼠DLL1全长基因真核表达载体,并在肿瘤细胞中表达。方法：利用PCR特异性引物扩增出DLL1基因全长,将克隆的基因片段插入带绿色荧光蛋白的真核表达载体pIRES2-EGFP质粒中。然后利用脂质体将重组质粒pIRES2-EGFP-DLL1转染进小鼠B16黑色素瘤细胞中,并通过G418筛选后选取生长良好、荧光强度高的三株单克隆进行mRNA水平DLL1表达的鉴定。结果：成功扩增小鼠DLL1的全长基因。克隆入质粒载体后,通过DNA序列测定证实其序列正确。将构建的pIRES2-EGFP-DLL1质粒转染小鼠B16黑色素瘤细胞,经过G418筛选和荧光显微镜观察后,挑选得到GFP阳性率90%以上的稳定转染细胞株。RT-PCR检测稳定转染细胞的mDLL1的表达显著增加,进一步证实了pIRES2-EGFP-DLL1的表达效能。结论：成功构建了小鼠DLL1基因的真核表达质粒,证实其在真核细胞B16中可以表达。     

人HCN2真核表达载体的构建及在HEK293细胞中的表达

目的：构建含有人HCN2基因的真核表达载体,并观察在人胚胎肾细胞（HEK293）中的表达情况。方法：对人HCN2基因全序列进行分析,进行oligo设计,通过PCR,扩增HCN2全长cDNA,通过双酶切（XhoI和BamHI）装入真核表达载体pIRES2-EGFP中,脂质体法转染入HEK293细胞中,利用真核表达载体中带有绿色荧光蛋白GFP报告基因,对转染效率进行监测,采用反转录-聚合酶链反应检测HCN2 mRNA表达,全细胞膜片钳技术检测HCN2通道电流。结果：测序及酶切结果表明HCN2基因正确,荧光显微镜下,转染细胞观察到绿色荧光,反转录-聚合酶链反应检测到HCN2 mRNA表达,膜片钳检测到hHCN2基因编码的通道电流。结论：成功地构建了HCN2真核表达载体并进行了起搏通道HCN2基因的异源性表达。     

The regulation of TACE catalytic function by its prodomain

Aim To study the function of the prodomain of ADAM17 (TACE) and to develop an approach for interfering with inflammation processes. Method The expression plasmids of the TACE ectodomain (T1300), prodomain (T591), signal peptide and prodomain (T648), full length (T2472), and the turncated TACE without prodomain (T57-T1824) were constructed and designated as pET-28a-T300, pET-28a-T591, pIRES2-EGFP-648, pEGFP-N1-T648, pIRES2-EGFP-T2472, and pIRES2-EGFP-T57-T1824, respectively. After Ni²⁺-NTA resin-affinity chromatography, the recombinant T591 and T1300 proteins were obtained and assayed by western blotting and circular dichroism. The experiment was carried out on THP1 cell lines stimulated by LPS in vitro. The inhibition of recombinant protein T591 to TACE activity was detected by ELISA and immunohistochemical detection. The expression plasmids (pIRES2-EGFP-T648, pIRES2-EGFP-T2472, and pIRES2-EGFP-T57-T1824) were used to transfect the U937 cells. HeLa cells were also transfected with pEGFP-N1-T648. The transfected U937 cells were then stimulated by LPS and the effect of expression plasmids on TNF-α secretion was detected by ELISA and flow cytometry (FCM). Results The recombinant prodomain protein inhibited 57% of the TNF-α secretion and mediated an accumulation of TNF-α on the surface of THP1 cells. An intense green fluorescence was seen in the membranes of HeLa cells transfected with pEGFP-N1-T648. The plasmid pIRES2-EGFP-T648 inhibited TNF-α secretion by 61.09% and mediated an accumulation of mTNF-α on the surface of the U937 cells. The secretion of sTNF-α and the level of the mTNF-α in the pIRES2-EGFP-T57-T1824 transfected cells gave no difference when compared with the pIRES2-EGFP transfected cells. Also the secretion of sTNF-α from the cells transfected by the plasmid pIRES2-EGFP-T2472 increased, while the level of mTNF-α decreased, compared with the pIRES2-EGFP-transfected cells. Conclusion The prodomain has dual effects and might be useful in the molecular design of an anti-inflammatory drug.     

B19病毒XA株VP1独特区真核表达系统的建立及鉴定

目的:克隆B19病毒XA株VP1u基因,构建真核重组表达载体.方法:从已构建好的B19病毒XA株原核表达载体中获得VP1u基因,将其克隆入真核表达载体plRES2-EGFP中,经酶切鉴定并测序验证后,获得真核表达载体plRES2-EGFP-VP1u.将其转染至HeLa细胞,提取细胞总蛋白,用Western blot技术检测VP1u蛋白的表达.结果:成功构建了携带人B19病毒VP1u基因的真核表达载体plRES2-EGFP-VP1u,荧光显微镜下可见pIRES2-EGFP-VP1u转染HeLa细胞后表达EGFP蛋白而发出绿色荧光,Western blot证明VP1u蛋白在HeLa细胞中表达.结论:成功构建了携带人B19病毒VP1u基因的真核表达载体plRES2-EGFP-VP1u并在HeLa细胞中正确表达,为今后B19病毒VP1u基因疫苗的研究奠定基础.     

Clusterin抑制人肾近曲小管上皮HK-2细胞的凋亡

Clusterin是一种硫酸糖蛋白.最近研究发现,clusterin具有抗凋亡作用,同时对肾细胞具有保护作用,但抗凋亡的具体机制仍不清楚.为研究clusterin及其不同功能区域在人肾近曲小管上皮HK-2细胞中的抗凋亡作用,构建了含有全长及缺失前导序列的clusterin重组质粒（分别命名为pIRES2-EGFP/cluac和pIRES2-EGFP/clubc）.将重组质粒转染人肾近曲小管上皮HK-2细胞后,检测转染细胞中clusterin的表达及其抗Na₂SeO₃（10μmol/L）诱导的凋亡作用.Western印迹显示,转染pIRES2-EGFP/cluac的HK-2细胞培养上清及细胞裂解液中均可检测到clusterin蛋白表达,但转染pIRES2-EGFP/clubc的HK-2细胞仅在裂解液中检测到clusterin,在培养上清液中未检测到该蛋白表达.流式细胞术检验显示,HK-2 /clubc细胞实验组出现明显凋亡峰,而 HK-2 /cluac细胞组则未见凋亡;两组的凋亡百分率之间也存在显著性差异（P<0.05）.以Cy3标记的Annexin V染色后于荧光显微镜下观察细胞凋亡情况与FCM检测结果基本一致.上述结果证明,clusterin有明显的抑制人肾近曲小管上皮HK-2细胞凋亡的作用;clusterin前导序列是其发挥抗凋亡作用的必需功能区域,提示clusterin抗凋亡作用是通过细胞外途径产生的.     

大鼠μ型阿片受体的pIRES2-EGFP质粒构建及其在HEK293细胞中的表达

提取大鼠脑组织总RNA,通过逆转录巢式PCR,扩增μ型阿片受体全长cDNA,克隆至pMD20-T载体中,测序鉴定,纠正点突变后,经酶切连接克隆入pIRES2-EGFP中,测序及酶切结果表明μ基因正确,μ-pIRES2-EGFP质粒构建成功.用脂质体法将μ-pIRES2-EGFP转染入HEK293细胞中,在荧光显微镜下,转染细胞可以观察到绿色荧光,应用免疫组化荧光可以观察到μ基因的高强度表达.     

Limited plasticity of mesenchymal stem cells cocultured with adult cardiomyocytes

In order to assess, in a controlled in vitro model, the differentiation potential of adult bone marrow derived stem cells we have developed a coculture procedure using adult rat cardiomyocytes and mesenchymal stem cells (MSCs) from transgenic GFP positive rats. We investigated in the cocultured MSCs the time course of cellular processes that are difficult to monitor in in vivo experiments. Adult rat cardiomyocytes and adult rat MSCs were cocultured for up to 7 days and analyzed by confocal microscopy. Several markers were studied by immunofluorescence technique. The fluorescent ST-BODIPY-Dihydropyridine was used to label calcium channels in living cells. Intracellular calcium was monitored with the fluorescent probe X-Rhod-1. Immunofluorescence experiments showed the presence of connexin-43 between cardiomyocytes and MSCs and between MSCs, while no sarcomeric structures were observed at any time of the coculture. We looked at the expression of calcium channels and development of voltage-dependent calcium signaling in cocultured MSCs. MSCs showed a time-dependent increase of labeling of ST-BODIPY-Dihydropyridine, reaching a relatively strong level after 72 h of coculture. The treatment with a non-fluorescent DHP, Nifedipine, completely abolished ST-BODIPY labeling. We investigated whether depolarization could modulate intracellular calcium. Depolarization-induced calcium transients increased in MSCs in relation to the coculture time. We conclude that MSCs cocultured with adult cardiomyocytes present preliminary evidence of voltage-dependent calcium modulation uncoupled with the development of nascent or adult myofibrils, thus showing a limited lineage specification and a low plasticity to differentiate in a full cardiomyocyte-like phenotype.     

Co-transfection and tandem transfection of HEK293A cells for overexpression and RNAi experiments

pIRES2-EGFP was employed and a non-target shRNA expressing plasmid was constructed to simulate overexpression and RNAi (RNA interference) experiments. Transfection of pIRES2-EGFP into HEK293A cells by cationic lipids VigoFect demonstrated that transfection efficiency increased in a dose-dependent manner with amount of DNA plasmid used, and optimal transfection time and cell density should be identified to reach a compromise of higher transfection efficiency and lower toxicity. Co-transfection experiments indicated that the two co-transfected plasmids were equivalently delivered into the same cells, and the co-transfection efficiency was rarely affected by cell density and proportion of the two plasmids. However, plasmid-receipted cells seemed indisposed to accept plasmid again during the second transfection, and very low co-transfection efficiency was observed in tandem transfection.     

Chondrogenesis enhanced by overexpression of sox9 gene in mouse bone marrow-derived mesenchymal stem cells

We investigated chondrogenesis of cell-mediated sox9 gene therapy as a new treatment regimen for cartilage regeneration. pIRES2-EGFP vector containing a full-length mouse sox9 cDNA was transfected into bone marrow-derived mesenchymal stem cells (MSCs) by lipofection and chondrogenic differentiation of these cells was evaluated. In vitro high density micromass culture of these sox9 transfected MSCs demonstrated that a matrix-rich micromass aggregate with EGFP expressing MSCs was positively stained by Alcian blue and type II collagen. Next, sox9 transfected MSCs were loaded into the diffusion chamber and transplanted into athymic mice to analyze in vivo chondrogenesis. A massive tissue formation in about 2mm diameter was visible in the chamber after 4 weeks transplantation. Histological examinations demonstrated that both Alcian blue and type II collagen were positively stained in the extracellular matrix of the mass while type X collagen was not stained. These results indicated that cell-mediated sox9 gene therapy could be a novel strategy for hyaline cartilage damage.